https://www.selleckchem.com/pr....oducts/mi-773-sar405
motherapy group had a low IgG level 1 year after trial inclusion. Conclusions Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin's lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection. (Funded by the Clinical Research Hospital Program of the French Ministry of Health and others; ClinicalTrials.gov number, NCT01516580.).Back
Like
Comment
Share
